A prescription for improving drug formulary decision making

Gordon D. Schiff; William L. Galanter; Jay Duhig; Michael J. Koronkowski; Amy E. Lodolce; Pam Pontikes; John Busker; Daniel Touchette; Surrey Walton; Bruce L. Lambert

doi:10.1371/journal.pmed.1001220

A prescription for improving drug formulary decision making

Gordon D. Schiff, William L. Galanter, Jay Duhig, Michael J. Koronkowski, Amy E. Lodolce, Pam Pontikes, John Busker, Daniel Touchette, Surrey Walton, Bruce L. Lambert

Communication Studies

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Original language	English (US)
Article number	e1001220
Journal	PLoS medicine
Volume	9
Issue number	5
DOIs	https://doi.org/10.1371/journal.pmed.1001220
State	Published - May 2012

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1371/journal.pmed.1001220

Cite this

@article{d9da7d610a3a404883390137e9bf63e4,

title = "A prescription for improving drug formulary decision making",

author = "Schiff, {Gordon D.} and Galanter, {William L.} and Jay Duhig and Koronkowski, {Michael J.} and Lodolce, {Amy E.} and Pam Pontikes and John Busker and Daniel Touchette and Surrey Walton and Lambert, {Bruce L.}",

note = "Funding Information: As part of a project sponsored by the US Attorney General Consumer and Prescriber Education Grant Program (funded by the Neurontin settlement ), we had the opportunity to bring together formulary committee chairs and participants from two public teaching hospitals and a university-based school of pharmacy. Our initiative, entitled the Formulary Leveraged Improved Prescribing (FLIP) Project was continued through the work of a US Agency for Healthcare Research and Quality–funded Center for Education and Research in Therapeutics . Funding Information: WG received grant funding from Abbott Labs- 2% FTE this year, Consulting with Walgreens (member of P&T Committee, ∼$5,000). JD had a summer student internship with Abbott Laboratories in Regulatory Affairs 2009–2010 7 k (2009) 8 k (2010). SW consulted for Abbott, Genentech, Primus. MK is a Consultant Pharmacist, Pharmacy and Therapeutics Committee, Catalyst Health Solutions, Inc, Rockville, MD. DT received unrestricted grant funding for research from Medco Health Solutions. BL consulted in last 3 years: Abbott (drug name confusion), Transcept. Stock ownership: Pharm I.R., Inc. (my own company, specializing in preventing and detecting drug name confusion errors). Expert witness testimony: Hernandez v. Schering (for Hernandez), Mason v. General Electric Company, et al. (for Mason). Grants received: Abbott (readability of MedGuides), Novartis (development of pharmacoepidemiologic methods), Ortho McNeil (safety of warfarin post orthopedic surgery), AHRQ (Tools for Optimizing Prescribing). Patents received: BLL Consulting, Inc. (related to preventing drug name confusions) Other: Board of Directors (unpaid) for Med-Errs, Inc. (drug name confusion). ",

year = "2012",

month = may,

doi = "10.1371/journal.pmed.1001220",

language = "English (US)",

volume = "9",

journal = "PLoS medicine",

issn = "1549-1277",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - A prescription for improving drug formulary decision making

AU - Schiff, Gordon D.

AU - Galanter, William L.

AU - Duhig, Jay

AU - Koronkowski, Michael J.

AU - Lodolce, Amy E.

AU - Pontikes, Pam

AU - Busker, John

AU - Touchette, Daniel

AU - Walton, Surrey

AU - Lambert, Bruce L.

N1 - Funding Information: As part of a project sponsored by the US Attorney General Consumer and Prescriber Education Grant Program (funded by the Neurontin settlement ), we had the opportunity to bring together formulary committee chairs and participants from two public teaching hospitals and a university-based school of pharmacy. Our initiative, entitled the Formulary Leveraged Improved Prescribing (FLIP) Project was continued through the work of a US Agency for Healthcare Research and Quality–funded Center for Education and Research in Therapeutics . Funding Information: WG received grant funding from Abbott Labs- 2% FTE this year, Consulting with Walgreens (member of P&T Committee, ∼$5,000). JD had a summer student internship with Abbott Laboratories in Regulatory Affairs 2009–2010 7 k (2009) 8 k (2010). SW consulted for Abbott, Genentech, Primus. MK is a Consultant Pharmacist, Pharmacy and Therapeutics Committee, Catalyst Health Solutions, Inc, Rockville, MD. DT received unrestricted grant funding for research from Medco Health Solutions. BL consulted in last 3 years: Abbott (drug name confusion), Transcept. Stock ownership: Pharm I.R., Inc. (my own company, specializing in preventing and detecting drug name confusion errors). Expert witness testimony: Hernandez v. Schering (for Hernandez), Mason v. General Electric Company, et al. (for Mason). Grants received: Abbott (readability of MedGuides), Novartis (development of pharmacoepidemiologic methods), Ortho McNeil (safety of warfarin post orthopedic surgery), AHRQ (Tools for Optimizing Prescribing). Patents received: BLL Consulting, Inc. (related to preventing drug name confusions) Other: Board of Directors (unpaid) for Med-Errs, Inc. (drug name confusion).

PY - 2012/5

Y1 - 2012/5

UR - http://www.scopus.com/inward/record.url?scp=84861567133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861567133&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.1001220

DO - 10.1371/journal.pmed.1001220

M3 - Article

C2 - 22629233

AN - SCOPUS:84861567133

SN - 1549-1277

VL - 9

JO - PLoS medicine

JF - PLoS medicine

IS - 5

M1 - e1001220

ER -

A prescription for improving drug formulary decision making

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this